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AdiponectinAbstract Background: Systemic inﬂammation appears to be a major factor linking COPD to met-
abolic disorders as comorbidities. Obesity is considered a state of chronic, low-grade inﬂammation
in which a greater production of pro-inﬂammatory cytokines overcomes the production of cyto-
kines with anti-inﬂammatory properties.
Aim of the work: To measure serum adiponectin (APN) level in COPD (obese and non obese)
during stable and acute exacerbation stage and to evaluate its role as a biomarker of systemic
inﬂammation
Subjects and methods: This study was conducted on 88 subjects; 68 male smokers with COPD (34
stable and 34 exacerbated each group reclassiﬁed into [17 obese and 17 non-obese]) and 20 age and
sex matched apparently healthy subjects as a control group. Serum APN level was measured with
ELIZA. Ventilatory function testing and body mass index (BMI) were performed in all patients and
control subjects.
Results: Serum APN level was approximately more than 3-fold higher in non-obese AECOPD
and stable COPD cases than obese. However, more than 2-fold higher in non-obese control than
obese. There was no correlation between adiponectin and FEV1, FEV1/FVC in COPD patients.
Conclusion: Serum adiponectin level was raised in non-obese COPD cases more than obese
COPD cases and the rise is more during exacerbation. In addition, serum adiponectin level was
raised in obese COPD cases during exacerbation and during stable conditions. A further rise in
serum APN in exacerbation period denotes that APN may also be a biomarker of exacerbation
and represents signiﬁcant prognostic marker for COPD disease.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.
584 S.S. Oraby et al.Introduction
Adipose tissue seems to interfere with systemic inﬂammation
in COPD patients by producing a large number of proteins,
known as ‘‘adipocytokines’’ or ‘‘adipokines’’ which are in-
volved in various processes such as metabolism, immunity
and inﬂammation. There is evidence that APN is an important
modulator of inﬂammatory processes [1].
APN is a secretory protein hormone, synthesized by adipo-
cytes and has important anti-inﬂammatory, anti-obesity and
anti-atherosclerotic effects [2].
APN exerts anti-inﬂammatory effects, by reducing inﬂam-
matory cytokines and inducing anti-inﬂammatory ones
through activation of all receptors. Several pathogenesis have
been suggested, including direct actions on inﬂammatory cells’
(inhibition of IL-6 production accompanied by induction of
the anti-inﬂammatory cytokines IL-10 and IL-1 receptor
antagonist [3], inhibition of endothelial Nuclear factor kappa
beta (NF-Kß)) signaling by c-AMP proteinkinase A dependent
pathway [4]. Its effect also extends to inhibit the production of
the pro-inﬂammatory cytokine TNF-a [5]. The exact mecha-
nism of APN participation in the COPD inﬂammation is still
a point of debate [6].
Adiponectin also has an endocrine effect (as a circulating
hormone acting on blood vessels, liver and skeletal muscles)
and an auto/paracrine effect (differentiation of preadipocytes
to adipocytes) [6].
Adiponectin and all of the known receptors for adiponectin
such as AdipoR1, AdipoR2, T-cadherin and calreticulin are
expressed on multiple cell types in the lung and APN has been
isolated from BAL ﬂuid [7–9].
Lower serum concentrations of APN may be associated
with decreased lung function in humans. It is therefore possible
that the lung is a target organ for APN signaling and conse-
quently, adiponectin derangements may be associated with dis-
eases of the lung [10].
Limited data are available on the role of APN in COPD,
with the exception of an increase in its levels in underweight
COPD patients and a marginal difference between stable phase
and exacerbation [11].Aim of the study
This study was carried out to measure serum adiponectin level
in COPD (obese and non obese) patients during stable and
acute exacerbation stage and to evaluate its role as a bio-
marker of systemic inﬂammatory response.
Subjects and methods
This case–control study was conducted at Chest Departments,
Al-Zahraa University Hospital. The ethics committee of Uni-
versity Hospital institute approved the study. An informed
written consent was obtained from all participants before their
enrollment into the study. This study was conducted on 88
subjects. They are divided into two groups:
 COPD group: Including 68 male smokers, COPD patients
(34 exacerbated and 34 stable). All of them had symptoms
of chronic airﬂow limitation and fulﬁlled criteria set outby (GOLD, 2011) [12] for diagnosis of COPD. All COPD
patients were smokers and had post-bronchodilator
(FEV1) less than 80% of the predicted value, along with
an FEV1/FVC not more than 70%. They had an increase
in FEV1 less than 200 ml or less than 12% of baseline value,
15–20 min after 2 puffs of inhaled salbutamol via a
metered-dose inhaler [12]. Thirty-four patients of them
had clinically stable COPD for at last 3 months and the
other 34 patients had clinical symptoms of COPD exacerba-
tion (increased dyspnea, sputum production or purulence)
[12].
 Control group: includes 20 age and sex-matched apparently
healthy nonsmoking volunteers.
Patients and control groups were reclassiﬁed according to
body mass index (BMI) into non-obese (BMI < 25 and
>18) and obese (BMI > 30) as follows:
1. Thirty-four stable COPD (17 obese patients and 17 non-
obese patients);
2. Thirty-four AECOPD (17 obese patients and 17 non-obese
patients); and
3. Control group (10 obese subjects and 10 non-obese
subjects).
 Overweight with BMIP 25 and 630 were not included in
this study [13].
Exclusion criteria
Patients with signiﬁcant comorbidities, including other lung
disease except from COPD, apparent heart failure, coronary
artery disease, renal or liver impairment or failure, diabetes
mellitus, history of cancer in any site, metabolic syndrome, col-
lagen and vascular disorders were excluded [13].
Study design
All subjects were subjected to the following:
1. Detailed medical history and clinical examination, as well
as history of any other co-morbidity that may rise the
APN level.
2. Body mass index (BMI) was calculated as (kg/m2).
3. Standard Laboratory tests (to exclude comorbid diseases),
e.g. CBC, ESR, urine analysis, fasting and postprandial
blood sugar, liver and renal function tests.
4. Plain chest radiography and ECG.
5. The ventilatory function tests were carried out using Spiro-
sift spirometry 5000 FUKUDa NENSHI before and after
bronchodilatation. Spirometric–indices were calculated
using best out of three technically satisfactory trials accord-
ing to the recommendations of the ATS (1987) [14]. The fol-
lowing parameters were recorded: FVC%, FEV1%, FEV1/
FVC%.
6. Blood samples for adiponectin were drawn prior to the ini-
tiation of treatment for COPD during exacerbation, stable
condition and for control group. Blood samples were col-
lected by vein puncture into plain tubes. Sera were obtained
by centrifugation at 1000g. for 5 min at room temperature;
the samples were stored at 70 until analysis.
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immunosorbent assay (ELIZA) using adiponectin ELIZAKit.
Statistical analysis
Data were analyzed by Microsoft Ofﬁce 2007 (excel) and Sta-
tistical Package for Social Science (SPSS) version 10. Data
were expressed as mean ± SD for quantitative variables. t-
Test and ANOVA were used when appropriate P< 0.05
was considered statistically signiﬁcant while p 6 0.01 is consid-
ered highly signiﬁcant.
Results
Clinical characteristics of COPD patients and healthy control
subjects are summarized in (Table 1). Both COPD group and
control group were age matched, while BMI was signiﬁcantly
increased in COPD group (p< 0.01). On the other hand all
spirometric indices (% predicted) were signiﬁcantly lower in
COPD group (p< 0.00).
Table 2 shows a highly signiﬁcant increase in serum APN
level in non-obese versus obese among the 3 studied groups
 By ANOVA test, there was highly signiﬁcant difference in
APN between non-obese groups (AECOPD, stable COPD,
and controls) as well as between obese groups (AECOPD,
stable COPD, and controls).
 By t-test, serum APN was highly signiﬁcant increased in
non-obese AECOPD than both non-obese stable and non-
obese control. Moreover, serum APN was highly signiﬁ-
cantly increased in obese AECOPD than obese control,
and it was non-signiﬁcantly differed between obese
AECOPD and stable COPD. Serum APN was highly signif-
icantly increased in stable COPD (obese and non-obese)
when compared to control group (obese and non-obese).
 Tables 3–5 show that serum APN did not correlate with
demographic-data and ventilatory function tests among
all studied subgroups.
Discussion
Serum adiponectin is a promising biomarker for respiratory
outcomes and other comorbidities. Many human studiesTable 1 Characteristics of healthy controls and COPD patients.
Items Group
COPD No. = 68
Mean ± SD
Age/years 53.43 ± 5.26
Sex Male
BMI (kg/m2) 29.33 ± 6.08
Smoking (pack/year) 30.97 ± 13.15
COPD Duration/year 17.13 ± 4.35
Spirometric indices
FVC% 60.71 ± 11.62
FEV1% 43.75 ± 0.75
FEV1/FVC% 48.83 ± 15.07
* Highly signiﬁcant.[15,16] indicate that circulating APN levels are raised in COPD
and associated with poor health outcomes, including increased
risk of exacerbations.
Many studies reported elevated serum APN level in under-
weight and normal weight COPD cases, but no available re-
searches were found discussing the role of serum APN in
obese COPD patients during acute exacerbation and during
stable conditions. Therefore, this study was conducted to ﬁnd
out if APN plays a role in such patients.
In the current study (Table 1) total COPD groups [No. 68],
and control were age matched and all of them were males.
In the current study (Table 2), serum APN levels were
remarkably elevated in non-obese versus obese in the same
group among the three studied groups. Serum APN level
was approximately more than 3-fold higher in normal weight
AECOPD and stable COPD cases than obese. However, it
was elevated more than 2-fold higher in normal weight control
than obese. These results were coinciding with a study carried
out by Andrea et al. (2013) [1] and Wouters et al. (2007) [2] as
they concluded that APN has anti-inﬂammatory and anti-
obesity effects.
These results were coinciding with a study carried out by
Tomoda et al. (2007) [11] who detected that adiponectin was
approximately 2-fold higher in normal weight stable COPD
cases than in controls.
Kirdar et al. (2009) [15] also detected that APN levels are
approximately 2-fold higher in COPD with normal BMI than
controls with direct correlation to the severity of the disease.
In the current study (Table 2) Tukey’s test demonstrated
that there was highly signiﬁcant increase in serum APN level
in non-obese COPD group (AECOPD or stable) versus control
groups (p 6 0.001); In addition, even in obese patients with
COPD (AECOPD and stable), serum APN levels were ele-
vated than control but less than in non-obese (5.17 ± 2.218)
(5.24 ± 1.8) versus (2.17 ± 1.232). In addition, there was
highly signiﬁcant increase in serum APN level in AECOPD ob-
ese versus stable groups (p 6 0.001). These results suggest that
respiratory distress caused by COPD, and elevated serum APN
levels (anti-obesity) may be one of causal factors of malnutri-
tion and cachexia in COPD, which may occur later on as a
component of systemic inﬂammatory response. A further rise
in serum APN in the exacerbation period denotes that it
may be a biomarker of inﬂammation in COPD patients during
exacerbation.
Similar results were reported by Kirdar et al. (2009) [15]
and Chan et al. (2010) [16] as they found that serum level ofp
Control No. = 20
Mean ± SD
52.24 ± 4.86 0.24
Male –
20.22 ± 3.57 0.01*
– –
– –
84.30 ± 5.14 0.001*
79.46 ± 0.27 0.000*
79.89 ± 7.05 0.000*
Table 2 Comparison of serum adiponectin level in AECOPD, stable COPD and control groups (non-obese and obese).
Items Group
Serum adiponectin (lg/mL) T-test
Non obese Obese
Mean ± SD Mean ± SD t p-Value
AECOPD 19.33 ± 1.73 5.17 ± 2.21 20.72 0.001 (HS)
Stable COPD 15.40 ± 2.67 5.24 ± 1.88 12.79 0.001 (HS)
Controls 5.37 ± 1.29 2.17 ± 1.23 5.663 0.001 (HS)
ANOVA F 143.665 9.796
P 0.000(HS) 0.000(HS)
Tukey’s test Stable and control 0.001 (HS) 0.001 (HS)
AECOPD and control 0.001 (HS) 0.001 (HS)
AECOPD and stable 0.001 (HS) 0.99 (NS)
Table 3 Correlation of serum APN level with demographic-




r p-Value R p-Value
Age 0.18 0.47 NS 0.06 0.80 NS
BMI 0.07 0.77 NS 0.06 0.80 NS
FEV1% 0.03 0.91 NS 0.09 0.71 NS
FVC% 0.33 0.19 NS 0.36 0.15 NS
FEV1/FVC 0.34 0.18 NS 0.55 0.21 NS
WBC 0.06 0.81 NS 0.24 0.34 NS
Table 4 Correlation of serum adiponectin level with demo-





r p-Value R p-Value
Age 0.07 0.76 NS 0.41 0.09 NS
BMI 0.45 0.06 NS 0.09 0.73 NS
FEV1% 0.10 0.68 NS 0.26 0.30 NS
FVC% 0.14 0.58 NS 0.06 0.18 NS
FEV1/FVC 0.36 0.15 NS 0.38 0.12 NS
WBC 0.01 0.95 NS 0.08 0.75 NS
Table 5 Correlation of serum APN level with demographic-




r p-Value r p-Value
Age 0.33 0.34 NS 0.21 0.54 NS
BMI 0.19 0.58 NS 0.62 0.05 NS
FEV1% 0.14 0.68 NS 0.09 0.79 NS
FVC% 0.12 0.73 NS 0.22 0.53 NS
FEV1/FVC 0.24 0.49 NS 0.26 0.46 NS
WBC 0.23 0.51 NS 0.42 0.22 NS
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subjects (P 6 0.001) and it was signiﬁcantly higher in COPD
during exacerbation as compared to stable states, which indi-
cate augmented inﬂammatory response. Therefore, they con-
cluded that circulating APN might represent a marker of
low-grade systemic inﬂammatory response in COPD and thus
APN may be an indirect marker of COPD severity.
Consistent with this notion, serum APN concentrations in
our results were raised during exacerbations compared with
periods of clinical stability.
Similarly, many authors [5,6,17,18] have demonstrated a
signiﬁcant increase of serum APN levels in COPD. Theyconcluded that serum level of anti-obesity APN was signiﬁ-
cantly higher even in COPD cases with normal BMI than that
in healthy subjects indicating that serum level of APN rise ear-
lier than body weight loss as a component of the systemic
inﬂammatory response and consequently may contribute to
the development of malnutrition.
Xie et al. in (2010) [19] reported that the concentration of
APN in the serum and induced sputum in AECOPD was sig-
niﬁcantly higher than those in stable COPD or healthy non-
smoking controls (P 6 0.01).
In the current study, there were non-signiﬁcant correlations
between serum APN concentrations and BMI, as well as ven-
tilatory function tests, and WBCs in stable COPD, AECOPD
and control (whether obese or non-obese) (Tables 4–5).
Zhao et al. (2012) [20] and Tomada et al. (2007) [11] did not
ﬁnd correlation between adiponectin and FEV1, FEV1/FVC
in COPD patients. Zhao et al. (2012) [20] proposed that the ab-
sence of correlation between pulmonary function and plasma
level of APN can explain that all patients with COPD in their
study were with mild and moderate bronchial obstruction.
Sin et al. (2002) [21] and Schachter et al. (2001) [22] ex-
plained that the major effect of obesity is on lung volume with
no direct effect on airway obstruction.
Indeed, relationship between APN concentrations and
accelerated decline in lung functions has been reported [23].
In a large population-based study of 2056 young partici-
pants of both sexes, serum APN concentrations were positively
associated with FVC and FEV1 without any signiﬁcant change
in FEV1/FVC ratio, independent of obesity [24].
Adiponectin as a biomarker of systemic inﬂammation 587On the other hand, two small previous cross-sectional stud-
ies of 31 and 15 patients with stable and established COPD,
without adjustment for obesity, showed a lack of correlation
between spirometric lung function and serum APN concentra-
tions [15].
Conclusions
APN represents a signiﬁcant prognostic marker for COPD dis-
ease. Serum APN level was raised in non-obese COPD cases
more than obese COPD cases and the rise is more during exac-
erbation. In addition, serum adiponectin level was raised in ob-
ese COPD cases during exacerbation and during stable
conditions. A further rise in serum adiponectin in exacerbation
period denotes that adiponectin may also be a biomarker of
exacerbation.
Recommendations
Further study is needed on a wide scale in COPD patients
especially obese to assess the level of adiponectin in serum
and in sputum during exacerbation and stable conditions.
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